Distinct Treatment Outcomes of Antiparasitic Therapy in *Trypanosoma cruzi*-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes

**Maria C. Albareda**¹, **Maria A. Natale**¹, **Ana M. De Rissio**¹, **Marisa Fernandez**¹, **Alicia Serjan**², **Maria G. Alvarez**³, **Gretchen Cooley**⁴, **Huifeng Shen**⁴, **Rodolfo Viotti**², **Jacqueline Bua**¹, **Melisa D. Castro Eiro**¹, **Myriam Nuñez**⁵, **Laura E. Fichera**¹, **Bruno Lococo**³, **Karenina Scollo**¹, **Rick L. Tarleton**⁴ and **Susana A. Laucella**¹,⁴

¹Instituto Nacional de Parasitología Dr. M. F. del Chabén, Buenos Aires, Argentina, ²Hospital Fernandez, Buenos Aires, Argentina, ³Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina, ⁴Center for Tropical and Emerging Global Diseases, Athens, GA, United States, ⁵Department of Mathematical Physics, Facultad Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

**Background:** In contrast to adults, *Trypanosoma cruzi*-infected children have more broadly functional *Trypanosoma cruzi*-specific T cells, and the total T-cell compartment exhibits fewer signs of immune exhaustion. However, not much is known about the link between immunocompetence and the treatment efficacy for human Chagas disease.

**Methods:** Using cytokine enzyme-linked immunosorbent spot (ELISPOT) polychromatic flow cytometry, cytometric bead assay, multiplex serologic assays and quantitative PCR, we evaluated *T. cruzi*-specific T-cell and antibody immune responses, T-cell phenotypes and parasitemia in children in the early chronic phase of Chagas disease undergoing anti-*Trypanosoma cruzi* treatment.

**Results:** Treatment with benznidazole or nifurtimox induced a decline in *T. cruzi*-specific IFN-γ- and IL-2-producing cells and proinflammatory cytokines and chemokines. T-cell responses became detectable after therapy in children bearing T-cell responses under background levels prior to treatment. The total frequencies of effector, activated and antigen-experienced T cells also decreased following anti-*T. cruzi* therapy, along with an increase in T cells expressing the receptor of the homeostatic cytokine IL-7. Posttreatment changes in several of these markers distinguished children with a declining serologic response suggestive of successful treatment from those with sustained serological responses in a 5-year follow-up study. A multivariate analysis demonstrated that lower frequency of CD4⁺CD45RA⁻CCR7⁻CD62L⁻ T cells prior to drug therapy was an independent indicator of successful treatment.
CONCLUSIONS:

These findings further validate the usefulness of alternative metrics to monitor treatment outcomes. Distinct qualitative and quantitative characteristics of T cells prior to drug therapy may be linked to treatment efficacy.

Keywords: *Trypanosoma cruzi*, T cells, benznidazole, nifurtimox, pediatric infection

INTRODUCTION

Therapy with benznidazole or nifurtimox is recommended during both acute and early chronic phases of *Trypanosoma cruzi* infection, and the efficacy of treatment is typically assessed by tracking a decline in serological responses over time posttreatment. The rate of conversion to negative serology by conventional tests is high when treatment is provided during the first year of life (1), and the treatment of 5- to 14-year-old children resulted in a slower decay of *T. cruzi*-specific antibodies over time (2, 3). However, treatment in adult chronic patients is not widely used mainly because of the lack of early metrics of treatment efficacy. Direct parasite detection is difficult prior to treatment, and thus, failure to detect parasites after treatment is not a failproof way to determine efficacy. We have shown that the use of a multiplex-based serologic assay and the monitoring of T-cell responses were more sensitive tools to evaluate treatment efficacy in adult patients (4, 5).

A detailed characterization of the T-cell compartment in children in relatively early phases of the chronic infection showed that in contrast to adults with longer-term infections, *T. cruzi*-infected children have more broadly functional *T. cruzi*-specific T cells and exhibit fewer indicators of immune exhaustion (6, 7). These findings prompted the question of whether the surrogate parameters of treatment efficacy previously assessed in *T. cruzi*-infected adult subjects might change more rapidly in children. In the present study, we serially monitored cellular and humoral immune responses and parasitemia after the etiological treatment of children in the early chronic phase of *T. cruzi* infection. We found that posttreatment changes in a set of immune parameters distinguished children with declining serologic responses, indicative of successful treatment, from those with sustained serological responses after therapy.

MATERIALS AND METHODS

Study Subjects

Five- to Sixteen-year-old children were enrolled at the Instituto Nacional de Parasitología Dr. Mario Fatała Chaben (Buenos Aires, Argentina) and at the Hospital Eva Perón (Buenos Aires, Argentina). *T. cruzi* infection was determined by indirect immunofluorescence (IIF), hemagglutination (IHA) and ELISA assays (8). Age- and sex-matched children with negative serological findings were recruited as uninfected controls (*Table 1*). Etiological treatment consisted of 5 mg/kg per day of benznidazole for 60 days or 10 mg/kg per day of nifurtimox for 60 days. Clinical, serological and immunological analyses were conducted prior to treatment, at 6 and 12 months following treatment, and at yearly intervals thereafter. Children with any impaired health condition were excluded from the present study. This protocol (No. 14-0004) was approved by the Institutional Review Boards of the Hospital Eva Perón, and Centro Nacional de Genética, Buenos Aires, Argentina. Informed written consent was obtained from the parents of all children included in the study, and written assent was also obtained from children older than seven years of age.

Collection of Peripheral Blood Mononuclear Cells (PBMCs) and Sera

Approximately 10 mL of blood was drawn by venipuncture into heparinized tubes (Vacutainer; BD Biosciences). PBMCs were isolated by density gradient centrifugation on Ficoll-Hypaque (Amersham) and stored in liquid nitrogen at a density of 1.5 × 10^6^ PBMCs/mL in newborn bovine serum containing 10% DMSO. On the day of the assay, PBMCs were thawed and washed in RPMI media containing 10% newborn bovine serum, 100 units/mL penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine and 10 mM Hepes buffer. The cell viability was assessed by trypan blue staining with a viability range of 80–90%. An additional two milliliters of blood was collected, allowed to coagulate at 37°C and centrifuged at 1,000 g for 15 min for sera separation. Due to sample availability, assays were not run for all samples.

Antigens

Protein lysate from *T. cruzi* amastigotes was obtained by freeze/thaw cycles, followed by sonication as previously reported (9). Thirteen peptides 9–10 amino acids in length derived from trans-sialidase proteins and bearing high binding affinities for the six most common class I HLA supertypes were synthesized by Pepscan Systems (Lelystad, the Netherlands). Lyophilized peptides were dissolved at 10–20 mg/mL in DMSO, aliquoted and stored at −20°C.

IFN-γ and IL-2 Enzyme-Linked Immunosorbent Spot (ELISPOT) Assays

The number of *T. cruzi* antigen-responsive IFN-γ- and IL-2-secreting T cells was determined by *ex vivo* ELISPOT using commercial kits (BD Biosciences), as previously described (4, 9, 10).

Briefly, cryopreserved PBMCs were seeded at a concentration of 4 × 10^5^ cells/well in triplicate wells and stimulated with *T. cruzi* lysate (10 µg/mL), a peptide pool from the trans-sialidase protein family (5 µg/mL/peptide; 10), or with media alone for 16–20 h at 37°C and 5% CO2. The stimulation of PBMCs with 20 ng/mL of phorbol 12-myristate 13-acetate (PMA, Sigma) plus 500 ng/mL of ionomycin (Sigma) in media was used...
as a positive control for cytokine secretion. Spot-forming cells (SFCs) were automatically enumerated using the ImmunoSpot analyzer (CTL). The mean number of spots in triplicate wells was calculated for each condition, and the number of specific IFN-γ and IL-2-secreting T cells was calculated by subtracting the value of the wells containing media alone from the antigen-stimulated spot count. Responses were considered statistically significant if a minimum of 10 spots/4 × 10^5 PBMCs was present per well; additionally, this number was at least twice the value of that in the wells with media alone (5, 11).

### Whole Blood Surface Staining Assays

For phenotypic analysis of total CD4^+ and CD8^+ T cells, 50 μL of whole blood was incubated with different combinations of anti-human-CD4 peridinin chlorophyll (PerCP, clone Leu-3a), anti-CD8 (PerCP, clone Leu-3a), anti-CD45RA fluorescein isothiocyanate (FITC, clone HI100), anti-CD45RA allophycocyanin (APC, clone HI100), anti-CD27 phycoerythrin (PE, clone M-T271), anti-CD28 (PE, clone CD28.2), anti-CD127 (PE, clone Hil-7R-M21), anti-HLA-DR (FITC, clone TU36) (BD Biosciences) and anti-KLRG1 (APC, clone 2F1) (e-Bioscience), followed by red cell lysis and white cell fixation in FACS Lysing Solution (Pharmingen). Typically, 500,000 lymphocytes were acquired on the FACScalibur (Becton Dickinson Immunocytometry Systems) and analyzed by using FlowJo software (TreeStar, Inc.).

### Multiplex Serodiagnostic Assay

Serum specimens were screened for antibodies reactive to a panel of nine recombinant *T. cruzi* proteins in a Luminex-based format, as previously described (4, 12). The serologic responses to each individual *T. cruzi* protein were decreased during the study period if the MFI declined by 50% relative to that of a pretherapy sample assessed concurrently.

### Cytometric Bead Array (CBA)

CBA assays were conducted according to the manufacturer’s instructions (BD Biosciences) using cell supernatants derived from *T. cruzi*-antigen-stimulated PBMCs or PBMCs cultured with media alone. Stimulation with PMA plus ionomycin served as a positive control to ensure that lymphocyte stimulation conditions were appropriate. The samples were acquired on a FACScalibur flow cytometer and analyzed by using BD CBA Software, version 1.4.

### Quantitative *T. cruzi* DNA Amplification

Two and a half milliliters of peripheral blood collected from subjects after treatment with benznidazole was mixed with the same volume of 6 M guanidine hydrochloride and 0.2 M EDTA, pH 8 (GEB), and maintained at room temperature for 1 week and then at 4°C until further use. Sample DNA isolation and parasite quantification, amplifying a *T. cruzi* satellite sequence, were performed as previously described (13).

### Statistics

The normality of the variable distribution was assessed by using the Kolmogorov-Smirnov criterion. The results are presented as medians or medians and interquartile ranges.

Differences between groups were evaluated by the Mann-Whitney *U*-test or Student’s *t*-test. Univariate analysis was conducted by Fisher’s exact test, Wilcoxon rank sum test or two-sample *t*-test, as appropriate. The serologic treatment response was defined as a significant decrease in two out of three conventional serologic assays (i.e., 30% reduction in ELISA titers, and a 2-fold dilution by IHA or IIF) and a 50% reduction in the reactivity of at least two proteins in the multiplex assay. For multivariate analysis, a principal component (PC) analysis was conducted to reduce the dimensionality of a large number of interrelated variables. The eigenvalue-one criterion (Kaiser criterion) was used for extracting relevant PCs (eigenvalue >0.7). The candidate markers in the final logistic regression analysis were transformed into log scale and odds ratios with 95% confidence intervals. Associations between continuous variables were assessed using the nonparametric Spearman’s correlation coefficient test. To evaluate changes in immune parameters over time posttreatment compared to those at baseline, a linear mixed model with compound symmetry, time as a fixed effect and the serologic treatment response as an interaction term was used. Since a linear mixed model could not be applied to evaluate the changes of *T. cruzi*-specific antibodies, an ANOVA for repeated measures was applied for the available data. Two-tailed *P* < 0.05 were considered statistically significant. Statistical analysis was conducted using IBM SPSS Statistics v23.0 (IBM Corp) and the Analytical Software Statistix 8.0.

---

**TABLE 1** Baseline characteristics of the study population.

| Clinical group | n | Electrocardiographic findings prior to treatment | No. of subjects born in endemic areas | Year-range of residence in endemic areas | Age range (median years) | Sex |
|----------------|---|-----------------------------------------------|--------------------------------------|-----------------------------------------|--------------------------|-----|
| Serum positive | 52 | 8 ANE | 18^d | 0–13 | 5–16 (11) | 28 | 24 |
| Serum negative | 35 | 2 ANE | 8^a | 0–11 | 6–16 (10) | 15 | 20 |

---

^a^All children were born to *T. cruzi*-infected mothers.

^b^All children were living in Buenos Aires (non-endemic) at the time of the present study.

^c^Number of patients presenting electrocardiographic alterations.

^d^One child born in Paraguay, 10 children born in Bolivia and 7 children born in Argentina.

^e^One child born in Paraguay and 7 children born in Bolivia.

ANE, abnormal findings in electrocardiography not relevant for Chagas disease.
RESULTS

Clinical Characteristics and Tolerance to Drug Treatment in Children in the Early Stages of Chagas Disease

The T. cruzi-infected group included 18 children born in areas endemic for T. cruzi infection and 34 children born in Buenos Aires, Argentina, where T. cruzi infection is not endemic. Prior to treatment, electrocardiography revealed eight seropositive and two seronegative children who showed abnormal findings not related to Chagas disease (Table 1).

Forty-five children were treated with benznidazole, and because benznidazole was not available in the country, seven additional children were treated with nifurtimox. Mild adverse drug reactions were observed in eight out of the 40 (20%) subjects under treatment with benznidazole, while five subjects (12.5%) showed severe side effects that resulted in treatment suspension. The five children who received incomplete benznidazole dosing were then treated with nifurtimox. Cutaneous rash and dermatitis were the main adverse drug reactions with benznidazole treatment, whereas nifurtimox was well tolerated. No electrocardiographic changes related to Chagas disease were observed during the follow-up period.

Monitoring of IFN-γ and IL-2 Secreting T Cells Responsive to T. cruzi Antigens Following Treatment With Benznidazole or Nifurtimox

In this study, we measured IFN-γ- and IL-2-producing T cells in response to T. cruzi antigens in 41 children treated with benznidazole or nifurtimox, with a median follow-up of 36 months (range 12–60 months). For the analysis, children were grouped according to pretreatment (i.e., baseline) IFN-γ ELISPOT responses to an amastigote lysate into those with positive IFN-γ ELISPOT responses, as defined in the Materials and Methods, and those with IFN-γ ELISPOT responses under background levels. Four different kinetics of changes in ELISPOT responses were observed following treatment. Relative to pretreatment, levels of T. cruzi-specific T cells producing IFN-γ were decreased below background levels in 12 children (Table 2, Group 1; Figure 1A), while in 4 children, IFN-γ T-cell levels decreased at least 3-fold following treatment (Table 2, Group 2; Figure 1B). Eight of the 12 children in whom IFN-γ-producing T cells posttreatment had become undetectable within 12 months after treatment showed a subsequent rebound in T-cell responses between 24 and 48 months posttreatment (Figure 1A). An increase in T-cell responses was also observed in subjects who tested negative for T. cruzi-induced IFN-γ-producing cells prior to treatment (Table 2, Group 3; Figure 1C). In contrast, a smaller proportion of children showed no alterations in T-cell responses following drug therapy (Table 2, Group 4; Figure 1D). In addition, IL-2-producing T cells changed in concert with IFN-γ+ T-cell responses (Figures 1A–D).

T-cell responses specific for a set of HLA-I-restricted trans-sialidase peptides, which have been demonstrated as targets of CD8+ T-cell responses in chronic Chagas disease (10), were also measured in 28 children. These assays revealed that T. cruzi-specific CD8+ T-cell responses are modified after antiparasitic treatment (Figure 1A, Ch279 and Ch302; Figure 1B, Ch278; Figure 1C, Ch55, Ch244, and Ch256). Children treated with nifurtimox showed a similar pattern of T-cell responses compared to that of children treated with benznidazole (Table 2, Figure 1C, Ch257 and Ch244).

### TABLE 2 | Changes in IFN-γ ELISPOT T-cell responses specific for Trypanosoma cruzi antigens in children treated with benznidazole or nifurtimox.

| Patient group | IFN-γ ELISPOT responses | No. of subjects treated with benznidazole | Cumulative changes in ELISPOT responses (No. of subjects/total evaluated) | Total (%) | No. of subjects with decreasing T. cruzi antibodies/total evaluated (%)a |
|---------------|-------------------------|------------------------------------------|-------------------------------------------------------------------------|-----------|---------------------------------------------------------------------|
|               |                         |                                          | No. of months after initiation of treatment |                         |                                                     |
| 1             | Became undetectableb    | 12                                       | 6/12 24 36 48 60                                                       | 48%       | 10/12 (83%)                                                        |
| 2             | > 3-fold decreaseb      | 4                                        | 1/4 1/17 2/24 3/25 4/25 4/25                                          | 16%       | 2/4 (50)                                                          |
| 3             | Became detectablec      | 10                                       | 5/11 10/14 10/16 10/16 10/16                                          | 62.5%     | 6/10 (60)                                                          |
| 4             | Unchangedd              | 15                                       | 7/25 9/28 13/38 15/41 15/41 15/41                                     | 36.6%     | 3/15 (20)                                                          |

aIFN-γ T cells above background levels prior to treatment and became undetectable following treatment.
bIFN-γ producing T cells decreased by >3-fold relative to pretreatment levels.
cIFN-γ producing T cells are undetectable prior to treatment and became detectable following treatment.
dIFN-γ-producing cells did not change following treatment in eight children with IFN-γ T cells above background levels and seven children with IFN-γ T cells under background levels.

P = 0.032 compared with subjects in Group 2 (Fisher’s exact test).

P = 0.057 compared with subjects in Group 3 (Fisher’s exact test).

P = 0.057 compared with subjects in Group 3 (Fisher’s exact test).

P = 0.018 compared with subjects in Group 4 (Fisher’s exact test).
Cytokine and Chemokine Production Following Anti-T. cruzi Treatment

Next, we assessed the effect of anti-T. cruzi treatment on cytokine and chemokine production.

Cytokine concentrations representative of adaptive type 1, adaptive type 2, regulatory and proinflammatory profiles as well as chemokines were measured in the supernatant of PBMCs in response to stimulation with T. cruzi lysate or media alone. Prior to treatment, T. cruzi-infected children showed a mixed type1/type2/Treg profile, with increased levels of TNF-α, IL-6, and IL-10 compared with those of uninfected children (Figures 2A–C). T. cruzi-infected children also had increased concentrations of the inflammatory cytokines IL-1β (Figure 2D) and IL-8 (Figure 2E) and the chemokines IP-10, MCP-1 and MIG (Figures 2F–H) compared with those of the uninfected group. In addition, although the differences were not statistically significant, higher levels of RANTES were observed in T. cruzi-infected children than those in uninfected controls (Figure 2I). Among T. cruzi-infected subjects, no differences were observed between T. cruzi-stimulated cells and those stimulated with media alone, except for IL-1β, IP-10, and MIG (Figures 2D,F,H). In the experimental conditions assessed, IL-2, IL-4, IL-17, and IL-12p70 were not detected (data not shown).

Because a positive correlation was found between the number of IFN-γ-producing cells and the concentration of cytokines and chemokines (Supplementary Table 1), the analysis of the changes of these molecules posttreatment was performed separately between patients who had positive IFN-γ-ELISPot responses and those who had IFN-γ-producing cell levels below the background levels prior to treatment. Figure 3 shows the median concentration changes of the set of cytokines and chemokines evaluated. Among patients with positive baseline IFN-γ responses, the levels of IP-10 (Figure 3A), MCP-1 (Figure 3B) and MIG (Figure 3C) significantly decreased between 12 and 36 months posttreatment, whereas the levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and RANTES did not change posttreatment (data not shown). In contrast, among subjects with baseline IFN-γ-producing cell levels below background frequencies, the levels of IL-1β, IL-6, IL-8, IL-10, MCP-1, and TNF-α increased at 12 months posttreatment and decreased thereafter (Figures 3D–I), whereas those of IP-10, MIG and RANTES
remained unaltered posttreatment (data not shown). These changes in posttreatment profiles were similar between *T. cruzi*-infected samples and those derived from PBMCs with media alone.

**Differentiation, Activation, and Antigen-Experienced Profile of Total T Cells in Treated Children**

We then evaluated whether antiparasitic therapy may revert the high degree of activation and differentiation of T cells observed in *T. cruzi*-infected children (6, 7, 14). Total effector (CD45RA+CD28− and CD45RA+CCR7−CD62L−), activated (HLA-DR+) and antigen-experienced (CD45−KLRG-1+CD127−) CD4+ T cells were decreased after treatment with benznidazole or nifurtimox, reaching values similar to those of uninfected subjects within 24 months of follow-up (Figures 4A–D, Supplementary Figure 1). A decline in TCR stimulation posttreatment was also evidenced by an increase in the frequency of total CD4+ T cells expressing CD127, which serves as the IL-7 receptor (Figure 4E), and a decrease in CD4+CD127− T cells (Figure 4F). Etiological treatment also induced a reduction in effector (CD45RA+CD27−) (Figure 5A), effector memory (CD45RA−CD127−) (Figure 5B), CD127− (Figure 5C) and activated (HLA-DR+) (Figure 5D) CD8+ T cells.
**T. cruzi**-Specific Humoral Responses and Parasite Burden Following Anti-**T. cruzi** Treatment

Prior to treatment, all children were seropositive by the three conventional tests. **T. cruzi**-specific antibodies declined at 6 months following treatment (Table 3) and at the end of follow-up, 10 out of 52 (19.23%) treated children (i.e., nine children treated with benznidazole and one child treated with nifurtimox) were seronegative in at least 2 of 3 tests, with a median time of seroreversion of 48 months (range 12–60 months posttreatment), (Table 3).

Prior to treatment, the sera from the 45 **T. cruzi**-infected children evaluated using a Luminex-based multiplex assay (4, 5, 12) recognized five proteins on average (ranging from 2 to 8 proteins). At 6 months following treatment, 17 of the 45 patients (37.3%) showed significant decreases in one or more proteins (2.8 proteins on average) (Figure 6, Supplementary Figure 2).

Although the infection status of the subjects prior to treatment was not determined, quantitative PCR (qPCR) was used to detect **T. cruzi** DNA as a measure of treatment failure in posttreatment blood samples from 46 of the 52 children treated with benznidazole or nifurtimox. One (20 subjects) or two (26 subjects) blood samples were tested at a 1-year interval with a median follow-up of 48 months (ranging from 24 to 60 months) posttreatment. In all cases, the blood samples were negative for **T. cruzi** DNA.
FIGURE 4 | Phenotypic profiles of CD4$^+$ T cells in T. cruzi-infected children following drug treatment. PBMCs were stained with the indicated monoclonal antibodies and analyzed by flow cytometry. Lymphocytes were gated based on forward scattering and side scattering. CD4$^+$ T cells were then selected and analyzed for the different T-cell phenotypes. (A–F) Each point represents the percentage of CD4$^+$ T cells expressing a particular phenotype for single subjects prior to and after treatment. Median values are represented by horizontal lines. ****P < 0.0001; ***P < 0.001, **P < 0.01, and *P < 0.05. Changes posttreatment from baseline (time 0) were evaluated by a linear mixed model for repeated measures.

Posttreatment Changes in Immune Parameters Associated With Declining Serologic Response

We then evaluated the association between treatment-dependent changes in the profile of cytokines, chemokines and T-cell phenotypes and the distribution of the serologic treatment outcomes. Considering reversion to negative serology and significant decreases in antibody titers by at least two conventional serologic tests and the multiplex assay, the subjects were classified as those with declining T. cruzi-specific antibody levels (i.e., effectively treated) or those with sustained antibody responses (i.e., ineffectively treated). The kinetics of the changes in IFN-γ-secreting cells as well as those of IL-1β, IL-6, IL-8, IL-10, MCP-1, TNF-α, and effector T cells following treatment were different between patients with dissimilar serologic treatment outcomes. A marked decline in IFN-γ-producing cells (Tables 2, 4) and in the frequency of effector CD4$^+$ CD45RA$^+$ CD28$^-$ T cells after therapy was associated with effective treatment (Table 4). As indicated by the estimate value, at 36 months posttreatment, the number of IFN-γ-producing cells was 1.74-fold higher in patients with ineffective treatment than that in effectively treated patients. IL-1β, IL-6, IL-8, IL-10, MCP-1, and TNF-α presented different kinetics associated with an effective treatment outcome, with an increase at 12 months posttreatment, followed by a decline. Children with ineffective treatment showed milder changes in these biomarkers (Table 4).

Baseline Immune Profiles Associated With Declining Serologic Response Posttreatment

To explore whether pretreatment immunological parameters were associated with serologic treatment outcomes, a univariate and multivariate regression analysis that was conducted using the reduction in the levels of T. cruzi-specific antibodies as the outcome revealed that younger age during treatment, lower TNF-α levels and lower percentages of effector memory CD4$^+$ T cells were associated with effective treatment (Table 5). Although not statistically significant, higher frequencies of activated and differentiated memory CD4$^+$ T cells, higher IL-10 levels and lower numbers of IFN-γ-producing cells were associated with ineffective treatment (Table 5).
FIGURE 5 | Phenotypic profiles of CD8\(^+\) T cells in T. cruzi-infected children following T. cruzi therapy. PBMCs were stained with the indicated monoclonal antibodies and analyzed by flow cytometry. Lymphocytes were gated based on forward scattering and side scattering. CD8\(^+\) T cells were then selected and analyzed for the different T-cell phenotypes. (A–D) each point represents the percentage of CD8\(^+\) T cells expressing a particular phenotype for single subjects prior to and after treatment. Median values are represented by horizontal lines. ****\(P < 0.0001\); **\(P < 0.01\), and *\(P < 0.05\). Changes posttreatment from baseline (time 0) were evaluated by a linear mixed model for repeated measures.

When PC analysis was applied, we identified two distinct principal components (Supplementary Figure 3). PC1 was characterized by cytokines of the adaptive type 1, adaptive type 2 and T regulatory profiles, chemokines and effector CD4\(^+\) and CD8\(^+\) T-cell populations (accounting for 40.43% of the total variance in the data); PC2 comprised memory CD4\(^+\) and CD8\(^+\) T cells with different degree of differentiation, total activated CD4\(^+\) and CD8\(^+\) T cells, and IFN-\(\gamma\)-producing cells in response to T. cruzi antigens (accounting for 24.20% of total variance in the data). A logistic regression analysis constructed with immune parameters selected by the PC analysis (Supplementary Figure 3) showed that effector memory (CD45RA\(^-\)CCR7\(^-\)CD62L\(^-\)) CD4\(^+\) T cells were an independent variable associated with effective treatment (\(P = 0.023\), odds ratio = 0.60, and 95% CI = 0.39–0.93).

DISCUSSION

Despite extensive efforts, early metrics of treatment efficacy in clinical practice for the management of chronic Chagas disease are still lacking. Treatment outcomes are considered to be better (i.e., more cures) and easier to assess in children, as titers of anti-T. cruzi antibodies decline more rapidly after effective treatment (1–3). Therefore, the present study focused on treatment outcomes specifically in children followed up for 60 months posttreatment with benznidazole or nifurtimox. We identified a broad range of cytokines and chemokines as well as T-cell phenotypes differentially modified in children presenting declining serologic responses indicative of successful treatment.

Anti-T. cruzi treatment in children induced significant changes in the frequencies of T. cruzi-responsive IFN-\(\gamma\)-producing cells similar to those observed in adult patients (4, 5).
A posttreatment decrease to background levels in the number of IFN-γ-producing cells, followed by a rebound, was also observed in treated children. We previously showed that rebound CD4+ IFN-γ+ T cells are enriched in costimulatory functions compared with those present prior to treatment, consistent with the suppression of antigen load (5). Notably, changes in T-cell responses, either decreases or transient increases, were highly correlated with an early decline in T. cruzi-specific antibody levels, supporting the usefulness of monitoring parasite-specific T-cell responses during treatment. Likewise, the transient increase in the levels of the proinflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α along with the transient increase in the levels of IL-10 and MCP-1 in patients with low baseline levels of these molecules were associated with a successful outcome of anti-T. cruzi therapy. The decline in the levels of MIG, IP-10 and MCP-1 following treatment supports a potential cessation in the recruitment of T cells and monocytes at target tissues.

Anti-T. cruzi therapy also induced a reconstitution of the phenotype of total CD4+ and CD8+ T cells with a clear decrease in the number of effector, activated, effector memory and memory T cells with low proliferative capacity, as well as an increase in the number of T cells expressing the α chain of the IL-7 receptor (i.e., the CD127 marker). The decreased expression of the IL-7 receptor and the presence of highly differentiated T cells are distinct features of T-cell exhaustion (15, 16). The responsiveness of T cells to IL-7 is essential for the maintenance of memory T cells (16). Chronically T. cruzi-infected adults have a predominance of monofunctional T. cruzi-specific T-cell responses and a perturbed IL-7/IL-7R pathway (9, 17). Although T. cruzi-infected children have polyfunctional parasite-specific T-cell responses compared with those of adults, the total T-cell compartment shows signs of T-cell exhaustion (7). Recently, it has been shown that inflammation perturbs the IL-7 axis, promoting T-cell exhaustion (18). Therefore, a lessened inflammatory environment following treatment would account for a more resting immune status of total T cells and the increase in the CD4+CD127+ T-cell levels observed herein. Of note, the decline in effector CD4+CD45RA−CD28− T-cell levels was associated with a decline in T. cruzi-specific antibody levels, further indicating a favorable treatment outcome in these children.

Sather Velar et al. showed that in children, treatment with benznidazole led to a high activation status of circulating monocytes (19) and a shift toward a type 1-modulated profile with increased CD8+IFN-γ+ counterbalanced by CD4+IL-10+ T cells (20). Other studies in children have also reported a decrease in the serum levels of IFN-γ (21) and soluble adhesion molecules (22) after treatment with benznidazole. An improvement in antigen-specific CD8+ T-cell responses (23) and a decline in activated T-cells have also been shown in adult patients treated with benznidazole (24, 25).

The rate of seroreversion to negative reactivity by conventional serologic tests was in the same range as that reported by other studies in a similar cohort of Argentinean benznidazole-treated children (26, 27), but lower than that observed in Colombian children treated with nitifurinox (26). In addition, the rate of seroreversion to negative reactivity in children was not different from those reported in previous studies of adult patients treated with benznidazole, with a median follow-up of 36 months (i.e., 19% in children vs. 21% in adults) (27). However, a significant decrease in antibody levels at 6 months posttreatment by the multiplex assay and by conventional serologic tests was detected in children, an observation not generally found in adult patients (27). By the end of follow-up, the proportion of children with a decrease in T. cruzi-specific antibody levels by the multiplex assay reached 87.5% compared with the 68.7% of adult patients detected in our previous study (27). This faster decline in parasite-specific antibody levels, indicative of a favorable outcome, could explain the higher cure rates, determined by seroconversion to negative findings (i.e., 43–64%), reported for 5- to 14-year-old children with long-term follow-up (28, 29). Undetectable qPCR confirms that treatment failure was not evident in the present study group.

Because of the faster decline in antibody levels following benznidazole administration in children compared with that in adult subjects, we were able to set up clear outcomes of treatment in the present study group and explore the association between baseline measures of the different parameters evaluated and the outcome of the treatment. Effective treatment was

---

**TABLE 3 | Antibody titers by conventional serologic tests in T. cruzi-infected children treated with benznidazole or nitifurinox.**

| Time post treatment | ELISAb | IHAc | IIIf | No. of subjects with seroreversionf |
|---------------------|--------|------|------|-------------------------------|
| Baseline (n = 52)   | 0.38 (0.35–0.42)b | 1:128 (1:64–1:256)d | 1:512 (1:160–1:1024)b | 0 |
| Month 6 (n = 49)    | 0.36 (0.31–0.39) | 1:128 (1:32–1:256) | 1:512 (1:128–1:512) | 0 |
| Month 12 (n = 48)   | 0.33 (0.28–0.37) | 1:64 (1:32–1:128) | 1:256 (1:128–1:512) | 0 |
| Month 24 (n = 46)   | 0.32 (0.28–0.37) | 1:64 (1:32–1:128) | 1:256 (1:128–1:512) | 1 |
| Month 36 (n = 40)   | 0.30 (0.25–0.35) | 1:64 (1:32–1:128) | 1:128 (1:64–1:128) | 2 |
| Month 48 (n = 30)   | 0.26 (0.19–0.35) | 1:64 (1:32–1:128) | 1:96 (1:56–1:128) | 2 |
| Month 60 (n = 13)   | 0.27 (0.19–0.30) | 1:32 (NR–1:192) | 1:64 (1:48–1:128) | 5 |

aThe data are shown as median ODs and interquartile ranges.

bP < 0.0001 compared with month 6, 12, 24, 36, 48 and 60 posttreatment by ANOVA for repeated measures after log transformation of the data.

cP = 0.005 vs. month 6; P < 0.0001 vs. month 12; 24, 36 and 48; P = 0.005 vs. month 60 by ANOVA for repeated measures.

dP < 0.024 vs. month 6; P < 0.0001 vs. month 12; 24 and 48; P = 0.012 vs. month 60 by an ANOVA for repeated measures. IHA, hemagglutination; IIF, immunofluorescence.

fConversion to negative finding in two out of three or three out three conventional serologic tests.
TABLE 4 | Mixed model analysis of cytokine, chemokine and T cell-phenotype profiles for the association with serologic treatment response in children in the early stages of chronic Chagas disease following therapy with benznidazole or nifurtimox.

| Dependent variable | Median change from baseline (Posttreatment/Pretreatment ratio) | Estimate<sup>e</sup> | 95% CI       | P-value |
|-------------------|---------------------------------------------------------------|----------------------|--------------|---------|
|                   | Decreasing T. cruzi antibody titers (n = 9)<sup>c</sup> |          |             |         |
|                   | Unchanged T. cruzi antibody titers (n = 9)<sup>d</sup> |          |             |         |
| No. IFN-γ-secreting cells<sup>a</sup> |                                   |          |             |         |
| Month 6           | 0.98                                                      | 1.00     | 0.45        | −1.10, 2.00 | 0.56 |
| Month 12          | 0.36                                                      | 0.58     | 0.28        | −1.39, 1.96 | 0.74 |
| Month 24          | 0.37                                                      | 1.38     | 1.08        | −3.64, 2.53 | 0.14 |
| Month 36          | 0.086                                                     | 0.73     | 1.74        | 0.11, 3.39  | 0.037 |
| Month 48          | 0.70                                                      | 2.40     | 0.18        | −1.87, 2.24 | 0.86 |
| IL-1β<sup>b</sup> | Month 6                                                    | 5.84     | 0.48        | −1.39        | 0.24 |
|                   | Month 12                                                   | 17.58    | 0.92        | −2.76        | 0.032 |
|                   | Month 24                                                   | 0.70     | 0.54        | −0.95        | 0.56 |
|                   | Month 36                                                   | 0.85     | 0.49        | −0.24        | 0.84 |
|                   | Month 48                                                   | 0.022    | 0.44        | 0.08         | 0.97 |
| IL-8<sup>b</sup>  | Month 6                                                    | 5.68     | 0.59        | −1.28        | 0.12 |
|                   | Month 12                                                   | 20.04    | 0.76        | −2.53        | 0.005 |
|                   | Month 24                                                   | 0.30     | 0.39        | −0.94        | 0.40 |
|                   | Month 36                                                   | 0.88     | 0.79        | −0.68        | 0.41 |
|                   | Month 48                                                   | 0.025    | 0.29        | −0.32        | 0.81 |
| IL-10<sup>b</sup> | Month 6                                                    | 2.44     | 0.75        | −0.74        | 0.19 |
|                   | Month 12                                                   | 5.94     | 0.82        | −1.73        | 0.005 |
|                   | Month 24                                                   | 0.76     | 0.59        | −0.68        | 0.37 |
|                   | Month 36                                                   | 1.23     | 0.90        | −0.46        | 0.43 |
|                   | Month 48                                                   | 0.14     | 0.78        | −0.28        | 0.76 |
| MCP-1<sup>b</sup> | Month 6                                                    | 1.20     | 0.43        | −2.31        | 0.24 |
|                   | Month 12                                                   | 15.75    | 2.47        | −4.96        | 0.02 |
|                   | Month 24                                                   | 1.10     | 0.54        | −1.86        | 0.48 |
|                   | Month 36                                                   | 0.84     | 0.96        | −1.21        | 0.54 |
|                   | Month 48                                                   | 0.004    | 0.25        | 1.48         | 0.65 |
| TNF-α<sup>b</sup> | Month 6                                                    | 16.00    | 0.31        | −3.52        | 0.08 |
|                   | Month 12                                                   | 183      | 2.46        | −5.56        | 0.009 |
|                   | Month 24                                                   | 2.5      | 0.14        | −2.72        | 0.30 |
|                   | Month 36                                                   | 3.50     | 0.38        | −3.20        | 0.27 |
|                   | Month 48                                                   | 0.001    | 0.04        | −2.18        | 0.51 |
| CD4<sup>+</sup> CD45RA<sup>+</sup> CD28<sup>-</sup> | Month 6 | 0.67 | 1.54 | 0.72 | 0.21, 1.23 | 0.006 |
|                   | Month 12                                                   | 0.44     | 0.77        | 0.20         | 0.44 |
|                   | Month 24                                                   | 0.36     | 0.93        | −0.13        | 0.72 |
|                   | Month 36                                                   | 0.19     | 0.54        | −0.40        | 0.14 |
|                   | Month 48–60                                                | 0.30     | 0.68        | −0.30        | 0.22 |

<sup>a</sup>Measurements in the supernatant of T. cruzi-stimulated PBMCs belonging to the group of children with positive baseline IFN-γ-ELISPOT responses, as indicated in the Materials and Methods.

<sup>b</sup>Measurements in the supernatant of T. cruzi-stimulated PBMCs belonging to the group of children with baseline IFN-γ-ELISPOT responses below background levels, as indicated in the Materials and Methods.

<sup>c</sup>Group of children with significant decreases in T. cruzi-specific antibodies by conventional serologic tests and the multiplex assay as described in Materials and Methods.

<sup>d</sup>Subjects not matching definition in A.

<sup>e</sup>The estimate value of the group of children with unaltered T. cruzi-specific antibody titers compared with those with decreasing antibody titers posttreatment is shown for each time point. Italics values indicate significant changes over time posttreatment in the corresponding parameter.
observed in younger children in association with fewer signs of T-cell exhaustion and lower baseline levels of proinflammatory cytokines. Notably, the frequency of total effector memory (CD62L−CCR7−) CD4+ T cells was an independent indicator of successful treatment.

There may be several explanations for the association of a less-exhausted T-cell profile and successful treatment. In first place, a less-exhausted immune status in children might be accompanied by fewer survival niches for long-lived plasma cells, which might be responsible for maintaining the levels of circulating antibodies for long term, even in the absence of antigen stimulation (30, 31). The duration of these plasma cells survival niches and, consequently, of their resident plasma cells was likely terminated by the resolution of the focus. It is also likely that because T-cell responses in children are not exhausted (6, 7), the immune system has a chance to contribute to treatment efficacy, whereas in adults (9, 10, 32), there is a reduced chance for this contribution. In the experimental infection, benznidazole therapy was less efficacious in treating immunosuppressed mice (33, 34), and adjunct therapy with recombinant IL-12 enhanced the efficacy of benznidazole (35). However, further experimental studies are necessary to answer this question.

Collectively, this work documents that effective treatment outcomes in T. cruzi-infected children are accompanied by changes in parasite-specific T-cell responses and T-cell phenotypes supporting the beneficial
TABLE 5 | Univariate analysis of baseline factors associated with serologic response in children in the early stages of chronic Chagas disease treated with benznidazole or nifurtimox.

| Variable (Unit) | Effective treatment | P-value |
|-----------------|---------------------|---------|
| Age (years)     | Yes (n = 25)        | No (n = 27) | 0.002 |
|                 | 10 (6.5–12.5)       | 13 (10.7–14) |
| Born in endemic areas (%) | Yes (25) | No (27) | 0.7 |
|                 | 36                  | 30.7    |
| Sex (No. male/No. female) | Yes (15/11) | No (15/11) | 0.7 |
|                 | 11/15               | 15/11   |
| Anti-T. cruzi antibodies (OD) | Yes (25) | No (27) | 0.22 |
|                 | 0.40 (0.36–42)      | 0.38 (0.35–0.41) |
| No. IFN-γ-producing cells | Yes (15/11) | No (15/11) | 0.17 |
|                 | 42.5 (5.8–110.2)    | 11.0 (1.7–73.5) |
| No. IL-2-producing cells | Yes (25) | No (27) | 0.30 |
|                 | 2.5 (0.2–11.8)      | 0.5 (0.0–7.7) |
| IL-1 (pg/mL)    | Yes (25)            | No (27) | 0.11 |
|                 | 972 (72.2–7121.5)   | 4854 (1,967–6,714) |
| IL-6 (pg/mL)    | Yes (25)            | No (27) | 0.36 |
|                 | 14695 (813–27005)   | 16813 (1,1681–30,825) |
| IL-8 (pg/mL)    | Yes (25)            | No (27) | 0.14 |
|                 | 23160 (4392–55035)  | 31249 (24,584–38,043) |
| IL-10 (pg/mL)   | Yes (25)            | No (27) | 0.28 |
|                 | 13 (0.0–92.5)       | 61 (37.7–88.5) |
| IP-10 (pg/mL)   | Yes (25)            | No (27) | 0.59 |
|                 | 50 (0.0–157.5)      | 24 (13–196) |
| MCP-1 (pg/mL)   | Yes (25)            | No (27) | 0.90 |
|                 | 334 (0.0–1179)      | 171 (64.7–987) |
| MIG (pg/mL)     | Yes (25)            | No (27) | 0.25 |
|                 | 52.5 (0.0–178.8)    | 83 (15.5–451.7) |
| TNF-α (pg/mL)   | Yes (25)            | No (27) | 0.02 |
|                 | 157 (9.2–911.2)     | 1181.5 (469.2–1673.8) |
| CD4+CD45RA+HLA-DR+ (%) | Yes (25) | No (27) | 0.46 |
|                 | 11.0 (9.7–14.0)     | 12 (8.5–15.5) |
| CD4+CD45RA+CCR7+CD127− (%) | Yes (25) | No (27) | 0.92 |
|                 | 0.76 (0.43–1.4)     | 0.89 (0.30–1.67) |
| CD4+CD45RA+CCR7+CD62L− (%) | Yes (25) | No (27) | 0.45 |
|                 | 27.5 (24–31.8)      | 31 (28–36.5) |
| CD4+CD45RA+CCR7−CD62L− (%) | Yes (25) | No (27) | 0.15 |
|                 | 0.8 (0.2–1.9)       | 0.5 (0.2–0.6) |
| CD4+CD45RA+CCR7−CD62L+ (%) | Yes (25) | No (27) | 0.02 |
|                 | 3.0 (3.0–4.0)       | 6.0 (3.5–8.0) |
| CD4+CD45RA+CD28+ (%) | Yes (25) | No (27) | 0.06 |
|                 | 0.96 (0.35–1.63)    | 2.24 (0.52–3.64) |
| CD4+CD45RA+CD28− (%) | Yes (25) | No (27) | 0.88 |
|                 | 0.41 (0.12–0.97)    | 0.43 (0.18–0.69) |
| CD8+CD127+ (%)  | Yes (25)            | No (27) | 0.86 |
|                 | 16 (12.2–20)        | 16 (14–19.2) |
| CD8+CD127− (%)  | Yes (25)            | No (27) | 0.09 |
|                 | 14 (9.5–25.5)       | 23 (16.5–33) |
| CD8+CD45RA+CD127+ (%) | Yes (25) | No (27) | 0.84 |
|                 | 11.0 (9.7–14.0)     | 4.0 (3.7–5.2) |
| CD8+CD45RA+CD127− (%) | Yes (25) | No (27) | 0.93 |
|                 | 4.0 (3.0–6.0)       | 4.0 (2.2–6.0) |
| CD8+CD45RA+CD27− (%) | Yes (25) | No (27) | 0.34 |
|                 | 6 (0–10)            | 5.5 (4–7.2) |

aData for continuous variables are shown as medians (interquartile range).

bEffective treatment comprises a significant decrease in T. cruzi-specific antibody levels by two out of three conventional serologic tests (i.e., 30% reduction in ELISA and reduction in at least 2-fold dilution by hemagglutination or immunofluorescence techniques) and 50% reduction in the reactivity to at least two proteins in the multiplex assay. Italic values indicate P-value < 0.1.

effect of treatment in the early chronic phase of the infection.

AUTHOR CONTRIBUTIONS

SAL, RT, and RV: designed research studies; MCA, AD, GC, HS, MAN, MC, MGA, JB, LF, KS, RV, and SAL: performed experiments, acquired data, analyzed data; MN: statistics; AS, MF, MGA, and BL: Patient care; SAL, RT, and MCA: drafted the manuscript; SAL: provided funding.

FUNDING

This work was supported by grants from The National Institutes of Health [Grants R01AI083188 and R01A 1110346 to SAL]; the Ministerio de Salud de la Provincia de Buenos Aires, Argentina; and the Ministerio de Salud de la Nación, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SAL, MCA, JB, and LF are members of the Scientific Career, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. MAN and MC are CONICET Ph.D. fellows.

ACKNOWLEDGMENTS

We thank the patients of the Instituto Nacional de Parasitología Dr. Mario Fata l Chaben and Hospital Eva Perón, Argentina, who provided blood samples, the Diagnostic Department of the Instituto Nacional de Parasitología Dr. Mario Fata l Chaben, Argentina, for serological tests and blood extractions, Pablo Viotti for data management, Claudia Nose for technical assistance with figures and Dr. Mario Chen of the DMID International Clinical Studies Support Center (ICSSC) at FHI 360, for biostatistics advice.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2018.01958/full#supplementary-material
REFERENCES

1. Altcheh J, Corral R, Biancardi MA, Freilij H. Anti-F2/3 antibodies as cure marker in children with congenital Trypanosoma cruzi infection. Medicina (B Aires) (2003) 63:37.

2. Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yamotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. (1998) 59:526–9. doi: 10.4269/ajtmh.1998.59.526

3. Sosa-Estani S, Vitelli-Avelar DM, Massara RL, de Lana M, Pinto Dias JC, Teixeira-Carvalho A, et al. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect. (2008) 10:103–13. doi: 10.1016/j.micinf.2007.10.009

4. Albareda MC, Olivera GC, De Rissio AM, Postan M. Assessment of CD8+ T cell senescence and exhaustion in children with chronic Chagas disease. J Immunol. (2009) 49:1675–84. doi: 10.1086/648072

5. Alvarez MG, Bertocchi G, Cooley G, Albareda MC, Viotti R, Perez-Mazliah DE, et al. Treatment success in Trypanosoma cruzi infection is predicted by early changes in serially monitored parasite-specific T and B cell responses. PLoS Negl Trop Dis. (2016) 10:e0004657. doi: 10.1371/journal.pntd.0004657

6. Albareda MC, Olivera GC, De Rissio AM, Postan M. Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children. Am J Trop Med Hyg. (2010) 82:861–4. doi: 10.4269/ajtmh.2010.09-0664

7. Albareda MC, De Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti R, et al. Functional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults. PLoS Negl Trop Dis. (2013) 7(12):e2575. doi: 10.1371/journal.pntd.0002575

8. World Health Organization. Control of Chagas disease. World Health Organ Tech Rep Ser. (2012) 975:1–116.

9. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, et al. Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis. (2004) 189:909–18. doi: 10.1086/381682

10. Alvarez MG, Postan M, Weatherly DB, Minning A, Castro-Eiro M, Alvarez MC, Viotti R, et al. Polyfunctional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults. J Immunol. (2006) 174:830–3. doi: 10.4049/jimmunol.174.2.830

11. Laucella SA, Segura EL. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz. (2009) 104(Suppl. 1):167–80. doi: 10.1590/S0074-02762009000900023

12. Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, Minning A, et al. Efficacy of chemotherapy with benznidazole in children with indeterminate phase of Chagas’ disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol. (2006) 64:554–63. doi: 10.1111/j.1365-3083.2006.01843.x

13. Cutrullis RA, Moscatelli GE, Moroni S, Volta BJ, Cardoni RL, Alteche J, et al. Benznidazole therapy modulates interferon-γ and M2 macrophagic receptor autoantibody responses in Trypanosoma cruzi-infected children. PLoS ONE (2011) 6:e27133. doi: 10.1371/journal.pone.0027133

14. Laucella SA, Segura EL, Riarte A, Sosa EA. Soluble platelet selectin (P-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas’ disease. Clin Exp Immunol. (1999) 118:423–7. doi: 10.1046/j.1365-2249.1999.01070.x

15. Mateus J, Pérez-Antón E, Lasso P, Egui A, Roa N, Carriero B, et al. Antiparasitic treatment induces an improved cd8+ T cell response in chronic chagasic patients. J Immunol. (2017) 198:3170–80. doi: 10.4049/jimmunol.1602095

16. Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, Petitti M, et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother. (2013) 68:424–37. doi: 10.1093/jac/dks390

17. Vallez J, Monge-Maillo B, Gutierrez C, Norman FF, Lopez-Velez R, Perez-Molina JA. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Acta Trop. (2016) 164:117–24. doi: 10.1016/j.actatropica.2016.09.010

18. Bianchi F, Cucunubá Z, Gual F, González NL, Freilij H, Nicholls RS, et al. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. PLoS Negl Trop Dis. (2015) 9:e0003465. doi: 10.1371/journal.pntd.0003465

19. Viotti R, Vigliano C, Alvarez MG, Lococo B, Petti M, Bertocchi G, et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis. (2011) 5:e1314. doi: 10.1371/journal.pntd.0001314

20. Sosa-Estani S, de Bravo BH, de Bizoito LH, Canil S, Cura EN, Segura EL. Evolución serológica a largo plazo en niños infectados por Trypanosoma cruzi que cursan fase clínica indeterminada, tratados con benznidazol. Available online at: http://www.fac.org.ar/tec/chagas2/llave/md8/md804/sosaes.htm. (Accessed November 21, 2017).

21. Strieger ML, del Barco ML, Fabbro DL, Arias ED, Amicano NA. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop. (2004) 37:365–75.

22. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. (2003) 3:822–9. doi: 10.1038/nri1203

23. Tiburzy B, Szyka M, Iwata H, Chrobok N, Kulkarni U, Hirose M, et al. Persistent autoimmune-production by intermediates between short- and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullous acquisita. PLoS ONE (2013) 8:e83631. doi: 10.1371/journal.pone.0083631

24. Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez ER, Lococo B, et al. Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol. (2009) 183:4103–8. doi: 10.4049/jimmunol.0900852

14 September 2018 | Volume 9 | Article 1568
33. Toledo MJO, Machado GBN, Pereira MES, Brener Z. Results of treatment in mice immunosuppressed inoculated with different Trypanosoma cruzi strains. *Mem Inst Oswaldo Cruz* (1991) 86:237.

34. Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, Gazzinelli RT. Experimental chemotherapy against *Trypanosoma cruzi* infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. *J Infect Dis.* (2002) 186:823–8. doi: 10.1086/342415

35. Michailowsky V, Murta SM, Carvalho-Oliveira L, Pereira ME, Ferreira LR, Brener Z, et al. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of *Trypanosoma cruzi*. *Antimicrob Agents Chemother.* (1998) 42:2549–56.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Albareda, Natale, De Rissio, Fernandez, Serjan, Alvarez, Cooley, Shen, Viotti, Bua, Castro Eiro, Nunez, Fichera, Scillo, Tarleton and Laucella. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*